Pharmacogenetics of smoking cessation in general practice: Results from the Patch II and Patch in Practice trials

Nicotine and Tobacco Research

Volumn 13, Issue 3, 2011, Pages 157-167

  David, Sean P ^a,b,c   Johnstone, Elaine C ^d   Churchman, Michael ^e   Aveyard, Paul ^f   Murphy, Michael F G ^d   Munafò, Marcus R ^g  

^a SRI INTERNATIONAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1; BUNGAROTOXIN RECEPTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE BETA MONOOXYGENASE; NICOTINE; NICOTINIC RECEPTOR ALPHA4; NICOTINIC RECEPTOR BETA2; PROTEIN; PROTEIN DBH; PROTEIN DRD2; PROTEIN DRD4; PROTEIN HTR1A; PROTEIN OPRM1; PROTEIN TH; PROTEIN TPH1; SEROTONIN TRANSPORTER; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG;

CIGARETTE SMOKING; COMPARATIVE STUDY; DNA POLYMORPHISM; GENERAL PRACTICE; GENOMICS; GENOTYPE; HUMAN; META ANALYSIS; METHODOLOGY; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; TRANSDERMAL PATCH; UNITED KINGDOM;

EID: 79957897495     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntq246     Document Type: Review

References (109)

1. Abbot, N. C., Stead, L. F., White, A. R., & Barnes, J. (1998). Hypnotherapy for smoking cessation. Cochrane Database of Systematic Reviews, 2. doi: 10.1002/14651858.CD001008
2. Akil, M., Kolachana, B. S., Rothmond, D. A., Hyde, T. M., Weinberger, D. R., & Kleinman, J. E. (2003). Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. Journal of Neuroscience, 23, 2008-2013.
3. Aspinall, M. G., & Hamermesh, R. G. (2007). Realizing the promise of personalized medicine. Harvard Business Review, 85, 108-117, 165.
4. Aveyard, P., Brown, K., Saunders, C., Alexander, A., Johnstone, E., Munafò, M. R., & Murphy, M. (2007). Weekly versus basic smoking cessation support in primary care: A randomised controlled trial. Thorax, 62, 898-903. doi: 10.1136/thx.2006.071837
5. Balfour, D. J. (2002). Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Current Drug Targets-CNS & Neurological Disorders, 1, 413-421. doi: 10.2174/1568007023339076
6. Benwell, M. E., & Balfour, D. J. (1992). The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. British Journal of Pharmacology, 105, 849-856.
7. Berrettini, W. H., Bierut, L., Crowley, T. J., Cubells, J. F., Frascella, J., Gelernter, J., et al. (2004). Setting priorities for genomic research. Science, 304, 1445-1447. doi: 10.1126/science.304.5676.1445c
8. Berrettini, W. H., Wileyto, E. P., Epstein, L., Restine, S., Hawk, L., Shields, P., et al. (2007). Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biological Psychiatry, 61, 111-118. doi: 10.1016/j.biopsych.2006.04.030
9. Bierut, L. J., Cubells, J. F., Iacono, W. G., Li, M. D., Madden, P. A., Nelson, E. C., et al. (2007). Genetic research and smoking behavior. The Journal of the American Medical Association, 297, 809. author reply 810. doi: 10.1001/jama.297.8.809
10. Bilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004). The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology, 29, 1943-1961. doi: 10.1038/sj.npp.1300542
11. Brody, A. L., Mandelkern, M. A., Olmstead, R. E., Scheibal, D., Hahn, E., Shiraga, S., & McCracken, J. T. (2006). Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Archives of General Psychiatry, 63, 808-816. doi: 10.1001/archpsyc.63.7.808
12. Burke, W., & Psaty, B. M. (2007). Personalized medicine in the era of genomics. The Journal of the American Medical Association, 298, 1682-1684. doi: 10.1001/jama.298.14.1682
13. Cardon, L. R., Idury, R. M., Harris, T. J., Witte, J. S., & Elston, R. C. (2000). Testing drug response in the presence of genetic information: Sampling issues for clinical trials. Pharmacogenetics, 10, 503-510. doi: 10.1097/00008571-200008000-00003
14. Chen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., et al. (2004). Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. American Journal of Human Genetics, 75, 807-821. doi: 10.1086/425589
15. Coleman, T., McEwen, A., Bauld, L., Ferguson, J., Lorgelly, P., & Lewis, S. (2009). Protocol for the proactive or Reactive Telephone Smoking Cessation Support (PORTSSS) trial. Trials, 10, 26. doi: 10.1186/1745-6215-10-26
16. Colilla, S., Lerman, C., Shields, P. G., Jepson, C., Rukstalis, M., Berlin, J., et al. (2005). Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenetics and Genomics, 15, 393-398. doi: 01213011-200506000-00004
17. Corrigall, W. A., Coen, K. M., & Adamson, K. L. (1994). Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Research, 653, 278-284. doi: 10.1016/0006-8993(94)90401-4
18. Corrigall, W. A., Franklin, K. B., Coen, K. M., & Clarke, P. B. (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology, 107, 285-289. doi: 10.1007/BF02245149
19. David, S. P. (2010). Exploratory/developmental study of pharmacogenetic smoking cessation therapy (5R21DA027331-03). Retrieved June 22, 2010, from http://projectreporter.nih.gov/project_info_details.cfm?aid=7782802&icde=4244544
20. David, S. P., Brown, R. A., Papandonatos, G. D., Kahler, C. W., Lloyd-Richardson, E. E., Munafò, M. R., et al. (2007). Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine & Tobacco Research, 9, 821-833. doi: 10.1080/14622200701382033
21. David, S. P., Johnstone, E., Griffiths, S. E., Murphy, M., Yudkin, P., Mant, D., & Walton, R. T. (2002). No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics, 12, 265-268. doi:10.1097/00008571-200204000-00011
22. David, S. P., Johnstone, E. C., Murphy, M. F., Aveyard, P., Guo, B., Lerman, C., & Munafò, M. R. (2008). Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: New data from the Patch in Practice trial and pooled analyses. Drug and Alcohol Dependence, 98, 77-85. doi: 10.1016/j.drugalcdep.2008.04.013
23. David, S. P., & Munafò, M. R. (2008). Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics, 9, 1307-1321. doi: 10.2217/14622416.9.9.1307
24. David, S. P., Munafò, M. R., Murphy, M. F., Proctor, M., Walton, R. T., & Johnstone, E. C. (2008). Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: Follow-up of a randomised clinical trial of transdermal nicotine patch. The Pharmacogenomics Journal, 8, 122-128. doi: 10.1038/sj.tpj.6500447
25. David, S. P., Munafò, M. R., Murphy, M. F., Walton, R. T., & Johnstone, E. C. (2007). The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial. Nicotine & Tobacco Research, 9, 225-231. doi: 10.1080/14622200601078566
26. David, S. P., Strong, D. R., Munafò, M. R., Brown, R. A., Lloyd-Richardson, E. E., Wileyto, P. E., et al. (2007). Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: Analysis of pooled data from two clinical trials. Nicotine & Tobacco Research, 9, 1251-1257. doi: 10.1080/14622200701705027
27. Di Chiara, G., & Imperato, A. (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences of the United States of America, 85, 5274-5278. doi: 10.1073/pnas.85.14.5274
28. Evans, W. E., & Johnson, J. A. (2001). Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annual Review of Genomics and Human Genetics, 2, 9-39. doi: 10.1146/annurev.genom.2.1.9
29. Evans, W. E., & Relling, M. V. (1999). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science, 286, 487-491. doi: 10.1126/science.286.5439.487
30. Fiore, M. C., Bailey, W. C., Cohen, S. J., Dorfman, S. F., Goldstein, M. G., Gritz, E. R., et al. (2000). Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service.
31. Fiore, M. C., Jaén, C. R., Baker, T. B., Bailey, W. C., Benowitz, N. L., Curry, S. J., et al. (2008). Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: U.S. Department of Health and Human Services Public Health Service.
32. Fowler, G. (1979). General practitioners' advice against smoking. British Medical Journal, 2, 551. doi: 10.1136/bmj.2.6189.551
33. Fowler, G. (1982). Practising prevention. Smoking. British Medical Journal, 284, 1306-1308. doi: 10.1136/bmj.284.6325.1306
34. Fowler, G., Mant, D., Fuller, A., & Jones, L. (1989). The "Help Your Patient Stop" initiative: Evaluation of smoking prevalence and dissemination of WHO/UICC guidelines in UK general practice. Lancet, 1, 1253-1255. doi: 10.1016/S0140-6736(89)92342-8
35. Gourlay, S. G., Stead, L. F., & Benowitz, N. L. (1998). A meta-analysis of clonidine for smoking cessation. The Cochrane Library Issue 2, Oxford: Update Software.
36. GPRG. (1991). Prevalence of risk factors for heart disease in OXCHECK trial: Implications for screening in primary care. Imperial Cancer Research Fund OXCHECK Study Group. British Medical Journal, 302, 1057-1060. doi:10.1136/bmj.302.6784.1057
37. GPRG. (1993). Effectiveness of a nicotine patch in helping people stop smoking: Results of a randomised trial in general practice. British Medical Journal, 306, 1304-1308. doi: 10.1136/bmj.306.6888.1304
38. GPRG. (1994a). Effectiveness of health checks conducted by nurses in primary care: Results of the OXCHECK study after one year. Imperial Cancer Research Fund OXCHECK Study Group. British Medical Journal, 308, 308-312.
39. GPRG. (1994b). Randomised trial of nicotine patches in general practice: Results at one year. Imperial Cancer Research Fund General Practice Research Group. British Medical Journal, 308, 1476-1477.
40. GPRG. (1995). Effectiveness of health checks conducted by nurses in primary care: Final results of the OXCHECK study. Imperial Cancer Research Fund OXCHECK Study Group. British Medical Journal, 310, 1099-1104.
41. Gwinn, M., Guessous, I., & Khoury, M. (2008). "Intention to analyze" in pharmacogenomics studies. Cancer Epidemiology, Biomarkers & Prevention, 17, 740. doi: 10.1158/1055-9965. EPI-07-2929
42. Hajek, P., & Stead, L. F. (1998). The effect of aversive smoking for smoking cessation. The Cochrane Library Issue 2, Oxford: Update Software.
43. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
44. Huang, W., Payne, T. J., Ma, J. Z., & Li, M. D. (2008). A functional polymorphism, rs6280, in DRD3 is significantly associated with nicotine dependence in European-American smokers. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B, 1109-1115. doi: 10.1002/ajmg.b.30731
45. Hughes, J. R., Stead, L. F., & Lancaster, T. R. (1998). Anxiolytics and Antidepressants for Smoking Cessation. The Cochrane Library Issue 2, Oxford: Update Software.
46. Jackson, P. H., Stapleton, J. A., Russell, M. A., & Merriman, R. J. (1989). Nicotine gum use and outcome in a general practitioner intervention against smoking. Addictive Behaviors, 14, 335-341. doi: 10.1016/0306-4603(89)90064-6
47. Jamrozik, K., & Fowler, G. (1982). Anti-smoking education in Oxfordshire general practices. The Journal of the Royal College of General Practitioners, 32, 179-183.
48. Jamrozik, K., Fowler, G., Vessey, M., & Wald, N. (1984). Placebo controlled trial of nicotine chewing gum in general practice. British Medical Journal, 289, 794-797. doi: 10.1136/bmj.289.6448.794
49. Jamrozik, K., Vessey, M., Fowler, G., Wald, N., Parker, G., & Van Vunakis, H. (1984). Controlled trial of three different antismoking interventions in general practice. British Medical Journal, 288, 1499-1503. doi: 10.1136/bmj.288.6429.1499
50. Johnstone, E. C., Clark, T. G., Griffiths, S. E., Murphy, M. F., & Walton, R. T. (2002). Polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers: Seeking confirmation of the association in a follow-up study. Pharmacogenetics, 12, 585-587. doi:10.1097/00008571-200210000-00012
51. Johnstone, E. C., Elliot, K. M., David, S. P., Murphy, M. F., Walton, R. T., & Munafò, M. R. (2007). Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology, Biomarkers & Prevention, 16, 1065-1069. doi: 10.1158/1055-9965.EPI-06-0936
52. Johnstone, E. C., & Murphy, M. (2007). Interindividual differences in tobacco dependence: The impact of genetics. In F. Grogna (Ed.), Why People Smoke. Brussels, Belgium: European Network for Smoking Prevention.
53. Johnstone, E. C., Yudkin, P., Griffiths, S. E., Fuller, A., Murphy, M., & Walton, R. T. (2004). The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population. Addiction Biology, 9, 221-226. doi: 10.1080/13556210412331292226
54. Johnstone, E. C., Yudkin, P. L., Hey, K., Roberts, S. J., Welch, S. J., Murphy, M. F., et al. (2004). Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics, 14, 83-90. doi: 10.1097/00008571-200402000-00002
55. Jones, S., Sudweeks, S., & Yakel, J. L. (1999). Nicotinic receptors in the brain: Correlating physiology with function. Trends in Neurosciences, 22, 555-561. doi: 10.1016/S0166-2236(99)01471-X
56. Kasper, J. F., Mulley, A. G., Jr., & Wennberg, J. E. (1992). Developing shared decision-making programs to improve the quality of health care. QRB. Quality Review Bulletin, 18, 183-190.
57. Kawamoto, K., Lobach, D. F., Willard, H. F., & Ginsburg, G. S. (2009). A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Medical Informatics and Decision Making, 9, 17. doi: 10.1186/1472-6947-9-17
58. Klink, R., de Kerchove d'Exaerde, A., Zoli, M., & Changeux, J. P. (2001). Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. The Journal of Neuroscience, 21, 1452-1463.
59. Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y. M., Szumlanski, C. L., & Weinshilboum, R. M. (1996). Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6, 243-250. doi: 10.1097/00008571-199606000-00007
60. Lancaster, T., & Stead, L. F. (1998a). Mecamylamine (a nicotine antagonist) for Smoking Cessation. The Cochrane Library Issue 2. Oxford: Update Software. doi: 10.1002/14651858.CD001009
61. Lancaster, T., & Stead, L. F. (1998b). Silver Acetate for Smoking Cessation. The Cochrane Library Issue 2, Oxford: Update Software. doi: 10.1002/14651858.CD000191
62. Laviolette, S. R., & van der Kooy, D. (2004). The neurobiology of nicotine addiction: Bridging the gap from molecules to behaviour. Nature Reviews Neuroscience, 5, 55-65. doi: 10.1038/nrn1298
63. Lerman, C., Shields, P. G., Main, D., Audrain, J., Roth, J., Boyd, N. R., et al. (1997). Lack of association of tyrosine hydroxylase genetic polymorphism with cigarette smoking. Pharmacogenetics, 7, 521-524. doi: 10.1097/00008571-199712000-00012
64. Loughead, J., Wileyto, E. P., Valdez, J. N., Sanborn, P., Tang, K., Strasser, A. A., & Caporaso, N. E. (2009). Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Molecular Psychiatry, 14, 820-826. doi: 10.1038/mp.2008.132
65. Marteau, T. M., & Lerman, C. (2001). Genetic risk and behavioural change. British Medical Journal, 322, 1056-1059. doi: 10.1136/bmj.322.7293.1056
66. Marteau, T. M., Munafò, M. R., Prevost, A. T., Aveyard, P., Johnstone, E. C., Armstrong, D., et al. (2010). Impact of genetic feedback on adherence to nicotine replacement therapy: The Personalised Extra Treatment (PET) Trial. Paper presented at the Society for Research on Nicotine and Tobacco's 16th Annual Meeting, February 24-27, 2010, Baltimore, MD.
67. Marubio, L. M., Gardier, A. M., Durier, S., David, D., Klink, R., Arroyo-Jimenez, M. M., et al. (2003). Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. European Journal of Neuroscience, 17, 1329-1337. doi: 10.1046/j.1460-9568.2003.02564.x
68. McKinney, E. F., Walton, R. T., Yudkin, P., Fuller, A., Haldar, N. A., Mant, D., et al. (2000). Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics, 10, 483-491.
69. Merikangas, K. R., & Risch, N. (2003). Genomic priorities and public health. Science, 302, 599-601. doi: 10.1126/science.1091468
70. Mifsud, J. C., Hernandez, L., & Hoebel, B. G. (1989). Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Research, 478, 365-367. doi: 10.1016/0006-8993(89)91518-7
71. Munafò, M. R., Clark, T., Johnstone, E., Murphy, M., & Walton, R. T. (2004). The genetic basis for smoking behavior: A systematic review and meta-analysis. Nicotine & Tobacco Research, 6, 583-597. doi: 10.1080/14622200410001734030
72. Munafò, M. R., Elliot, K. M., Murphy, M. F., Walton, R. T., & Johnstone, E. C. (2007). Association of the mu-opioid receptor gene with smoking cessation. The Pharmacogenomics Journal, 7, 353-361. doi: 10.1038/sj.tpj.6500432
73. Munafò, M. R., Johnstone, E. C., Guo, B., Murphy, M. F., & Aveyard, P. (2008). Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenetics and Genomics, 18, 121-128. doi: 10.1097/FPC.0b013e3282f44daa
74. Munafò, M. R., Johnstone, E. C., Murphy, M., & Aveyard, P. (2008). "Intention to analyze" in pharmacogenomics studies. Cancer Epidemiology, Biomarkers & Prevention, 17, 740. doi: 10.1158/1055-9965.EPI-08-0099
75. Munafò, M. R., Johnstone, E. C., Murphy, M. F., & Aveyard, P. (2009). Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine & Tobacco Research, 11, 404-407. doi: 10.1093/ntr/ntp007
76. Munafò, M. R., Johnstone, E. C., Wileyto, E. P., Shields, P. G., Elliot, K. M., & Lerman, C. (2006). Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology, Biomarkers & Prevention, 15, 398-400.
77. Munafò, M. R., Timpson, N. J., David, S. P., Ebrahim, S., & Lawlor, D. A. (2009). Association of the DRD2 gene Taq1A polymorphism and smoking behavior: A meta-analysis and new data. Nicotine & Tobacco Research, 11, 64-76. doi: 10.1093/ntr/ntn012
78. Munafò, M. R., Zetteler, J. I., & Clark, T. G. (2007). Personality and smoking status: A meta-analysis. Nicotine & Tobacco Research, 9, 405-413. doi: 10.1080/14622200701188851
79. Murphy, M., Johnstone, E. C., & Walton, R. T. (2004). Genes, nicotine addiction, smoking behaviour and cancer. In P. Boyle, N. Gray, J. Henningfield, J. Seffrin & W. Zatonski (Eds.), Tobacco and Public Health: Science and Policy (pp. 629-642), Oxford, UK: Oxford University Press.
80. Neville, M. J., Johnstone, E. C., & Walton, R. T. (2004). Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutation, 23, 540-545. doi: 10.1002/humu.20039
81. Olausson, P., Engel, J. A., & Soderpalm, B. (2002). Involvement of serotonin in nicotine dependence: Processes relevant to positive and negative regulation of drug intake. Pharmacology Biochemistry and Behavior, 71, 757-771. doi: 10.1016/S0091-3057(01)00673-6
82. Peto, R., Lopez, A. D., Boreham, J., Thun, M., Heath, C., Jr., & Doll, R. (1996). Mortality from smoking worldwide. British Medical Bulletin, 52, 12-21.
83. Raw, M., McNeill, A., & West, R. (1998). Smoking cessation guidelines for health professionals-A guide to effective smoking cessation interventions for the health care system. Thorax, 53(Suppl. 5,), Pt 1), S1-S19. doi: 10.1136/thx.53.2008.S1
84. Raw, M., McNeill, A., & West, R. (1999). Smoking cessation: Evidence based recommendations for the healthcare system. British Medical Journal, 318, 182-185.
85. Roter, D. L., Erby, L., Larson, S., & Ellington, L. (2009). Oral literacy demand of prenatal genetic counseling dialogue: Predictors of learning. Patient Education and Counseling, 75, 392-397. doi: 10.1016/j.pec.2009.01.005
86. Russell, M. A., Feyerabend, C., & Cole, P. V. (1976). Plasma nicotine levels after cigarette smoking and chewing nicotine gum. British Medical Journal, 1, 1043-1046. doi: 10.1136/bmj.1.6017.1043
87. Russell, M. A., Merriman, R., Stapleton, J., & Taylor, W. (1983). Effect of nicotine chewing gum as an adjunct to general practitioner's advice against smoking. British Medical Journal, 287, 1782-1785. doi: 10.1136/bmj.287.6407.1782
88. Russell, M. A., Peto, J., & Patel, U. A. (1974). The classification of smoking by factorial structure of motives. Journal of the Royal Statistical Society Series A (General), 137, 313-333. doi: 10.2307/2344953
89. Russell, M. A., Stapleton, J. A., Feyerabend, C., Wiseman, S. M., Gustavsson, G., Sawe, U., & Connor, P. (1993). Targeting heavy smokers in general practice: Randomised controlled trial of transdermal nicotine patches. British Medical Journal, 306, 1308-1312. doi: 10.1136/bmj.306.6888.1308
90. Russell, M. A., Stapleton, J. A., Hajek, P., Jackson, P. H., & Belcher, M. (1988). District programme to reduce smoking: Can sustained intervention by general practitioners affect prevalence? Journal of Epidemiology and Community Health, 42, 111-115. doi: 10.1136/jech.42.2.111
91. Russell, M. A., Sutton, S. R., Feyerabend, C., Cole, P. V., & Saloojee, Y. (1977). Nicotine chewing gum as a substitute for smoking. British Medical Journal, 1, 1060-1063. doi: 10.1136/bmj.1.6068.1060
92. Russell, M. A., Wilson, C., Feyerabend, C., & Cole, P. V. (1976). Effect of nicotine chewing gum on smoking behaviour and as an aid to cigarette withdrawal. British Medical Journal, 2, 391-393. doi: 10.1136/bmj.2.6032.391
93. Russell, M. A., Wilson, C., Taylor, C., & Baker, C. D. (1979). Effect of general practitioners' advice against smoking. British Medical Journal, 2, 231-235. doi: 10.1136/bmj.2.6184.231
94. Shield, A. J., Thomae, B. A., Eckloff, B. W., Wieben, E. D., & Weinshilboum, R. M. (2004). Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Molecular Psychiatry, 9, 151-160. doi: 10.1038/sj.mp.4001386
95. Silagy, C., & Ketteridge, S. (1998). The Effectiveness of Physician Advice to Aid Smoking Cessation. The Cochrane Library Issue 2. Oxford: Update Software.
96. Silagy, C., Lancaster, T., & Fowler, G. (1998). Training Health Professionals in Smoking Cessation. The Cochrane Library Issue 2. Oxford: Update Software. doi: 10.1002/14651858.CD000214
97. Silagy, C., Mant, D., Fowler, G., & Lancaster, T. (1998). Nicotine Replacement Therapy for Smoking Cessation. The Cochrane Library Issue 2. Oxford: Update Software.
98. Stapleton, J. A., Lowin, A., & Russell, M. A. (1999). Prescription of transdermal nicotine patches for smoking cessation in general practice: Evaluation of cost-effectiveness. Lancet, 354, 210-215. doi: 10.1016/S0140-6736(99)90001-6
99. Stapleton, J. A., Russell, M. A., Feyerabend, C., Wiseman, S. M., Gustavsson, G., Sawe, U., & Wiseman, D. (1995). Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction, 90, 31-42. doi: 10.1046/j.1360-0443.1995.901316.x
100. Stead, L. F., & Hughes, J. R. (1998). Lobeline for Smoking Cessation. The Cochrane Library Issue 2. Oxford: Update Software. doi: 10.1002/14651858.CD000124
101. Teutsch, S. M., Bradley, L. A., Palomaki, G. E., Haddow, J. E., Piper, M., Calonge, N., et al. (2009). The evaluation of genomic applications in practice and prevention (EGAPP) initiative: Methods of the EGAPP Working Group. Genetics in Medicine, 11, 3-14. doi: 10.1097/GIM.0b013e318184137c
102. Uhl, G. R., Drgon, T., Johnson, C., Walther, D., David, S. P., Aveyard, P., et al. (2010). Genome-wide association for smoking cessation success: Participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics, 11, 357-367. doi: 10.2217/pgs.09.156
103. Uhl, G. R., Liu, Q. R., Drgon, T., Johnson, C., Walther, D., Rose, J. E., et al. (2008). Molecular genetics of successful smoking cessation: Convergent genome-wide association study results. Archives of General Psychiatry, 65, 683-693. doi: 10.1001/archpsyc.65.6.683
104. USDHHS. (1988). The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services (USDHHS), Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health.
105. Wang, J., & Li, M. D. (2010). Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology, 35, 702-719. doi: 10.1038/npp.2009.178
106. Walton, R. T., Johnstone, E., Munafò, M. R., Neville, M., & Griffiths, S. (2001). Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy. Trends in Molecular Medicine, 7, 70-76. doi: 10.1016/S1471-4914(01)01915-3
107. Welton, N. J., Johnstone, E. C., David, S. P., & Munafò, M. R. (2008). A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine & Tobacco Research, 10, 231-240. doi: 10.1080/14622200701767761
108. White, A. R., Rampes, H., & Ernst, E. (1998). Acupuncture in Smoking Cessation. The Cochrane Library Issue 2. Oxford: Update Software. doi: 10.1002/14651858.CD000009
109. Yudkin, P., Munafò, M. R., Hey, K., Roberts, S., Welch, S., Johnstone, E., & Walton, R. T. (2004). Effectiveness of nicotine patches in relation to genotype in women versus men: Randomised controlled trial. British Medical Journal, 328, 989-990. doi: 10.1136/bmj.38050.674826.AE